Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anabolic Therapy in Postmenopausal Osteoporosis
NCT05010590Phase 4Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2022
- Primary completion
- Oct 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of romosozumab, denosumab in postmenopausal osteoporosis, sponsored by Massachusetts General Hospital. Started Mar 2022; status: active, not recruiting.
02
Drugs
romosozumabdenosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT05010590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05010590.